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Abstract: The presence of mural calcification has, for decades, been recognized as a marker for 
atheromatous plaque in the coronary arteries and the aorta, but only in the past decade has the 
application of noncontrast computed tomography (CT) been shown to be a reproducible, safe, 
and convenient test, which now is available worldwide. However, awareness of coronary artery 
calcium scanning is insufficient and the practitioner must be aware of the available literature as 
well as understanding clinical recommendations for applications and interpretation. It is best 
applied in the medium/intermediate risk, asymptomatic adult regardless of ethnicity across 
broad age ranges for both men and women; additional prognostic information is also afforded 
from the calcium distribution in the coronary artery system. Additionally, information can 
also be derived from the same CT scan regarding heart and aorta size and assessment of the 
epicardial fat pad (an anatomic marker for the metabolic syndrome). Details of how this test 
can aid in cardiovascular risk assessment and management in adults are provided.
Keywords: coronary artery calcium, coronary artery disease, electron beam computed 
  tomography, multidetector computed tomography, National Cholesterol Education Program 
Adult Treatment Plan III (NCEP ATP III), epicardial fat
Introduction
In 2004, 17.1 million individuals died of cardiovascular diseases, representing 29% of 
all global deaths; in the United State alone 650,000 individuals each year present with 
an acute coronary event as the initial symptom of developed coronary artery disease 
(CAD).1 In up to 20% of such individuals, this is their first and last (ie, fatal) symptom. 
Furthermore, it has been shown that 68% of acute coronary events2 occur in arteries 
that prior to the event were without a hemodynamically significant obstructive lesion 
as might have been defined by stress testing or direct, invasive angiography. It has 
been estimated that up to 75% of asymptomatic individuals destined to suffer from 
coronary heart disease were not aware of their sub-clinical atherosclerosis as they had 
no symptoms and may well have passed a standard stress test. These observations 
and others decry the need for a diagnostic tool to estimate focal severity of coronary 
  sub-clinical atherosclerosis in asymptomatic individuals that is more sensitive than 
stress testing and a more accurate predictor of medium and long term events than 
office based conventional Framingham risk factor analysis.
Coronary artery calcification (CAC) and coronary atherosclerosis was described by 
Virchow3 in 1858 as ‘plates of bone’. In 1961 Blankenhorn4 found, in 3,500   coronary Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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segments from autopsies, that all CAC was associated with 
intimal atherosclerosis. The first description of CAC using 
X-ray computed tomography (CT [electron beam CT or 
EBT]) was in 1987.5 In 1990, Agatston and colleagues6 used 
  high-resolution, thin collimation, ‘step and shoot’, ECG-
gated ‘heartscans’ and introduced the ‘Agatston’ total calcium 
scoring method, now almost universally applied in published 
research studies using conventional noncontrast CT (EBT 
and/or 64+-slice multidetector CT [MDCT]).
During the past 20 years, literally thousands of papers 
on CAC scoring have been published defining the role of the 
  coronary calcium score in qualifying coronary atherosclerosis. 
In particular, data have shown its clinical value, incremental 
and complementary to conventional risk factors, as an aid 
to diagnostics and prognostication in patients at medium/
intermediate risk for coronary disease. Additionally, more 
recent investigations have indicated that there remains further 
information that can be derived from the low radiation dose, 
noncontrast ‘heartscan’. These include data regarding the 
applicability of CAC across ethnic sub-groups, use of CAC 
for prognostication in the elderly, use of CAC in defining 
‘heart age’, defining CAC distribution in the coronary system 
as an additional factor above CAC score alone, and looking 
beyond the coronary arteries – regarding left ventricular size, 
aortic root/thoracic aorta diameter, and epicardial fat.
In this context, CAC quantitation has been the subject 
of extensive investigations (Table 1) that have confirmed its 
incremental value above conventional measures of predicting 
cardiovascular outcomes in asymptomatic individuals.7–15
CAC scanning was incorporated into the European 
Guidelines on Cardiovascular Disease Prevention in Clini-
cal Practice (2003)16 stating that “Coronary calcium scan-
ning is thus especially suited for patients at medium risk”; 
thus supporting use of CAC to supplement conventional 
risk analysis. The American Heart Association Guidelines 
for Cardiovascular Disease Prevention in Women (2004) 
listed the finding of CAC as an example of subclinical 
cardiovascular disease placing certain women in the higher 
10-year risk category stating that “some patients with 
  subclinical CVD will have .20% 10-year CHD risk and 
should be elevated to the high-risk category”.17
It is essential that clinicians understand what the CAC 
score provides in terms of diagnosis and the implications 
especially for medium to long term prognosis in individual 
patients The purpose of this review is to define a framework 
based upon published literature and the author’s experience 
for the incorporation of CAC scanning into the current 
practice paradigm of the FRS18 and the National   Cholesterol 
Education Program Adult Treatment Plan III (NCEP 
ATP III) guidelines,19 by providing recommendations for 
patient selection and cardiovascular risk assessment and man-
agement of medium/intermediate risk asymptomatic adults. 
Furthermore, new data ‘beyond the coronary arteries’ that can 
be derived from the noncontrast CT regarding   cardiovascular 
health are reviewed.
Overview of CAC
EBT utilizes a rotating electron beam to acquire triggered, 
tomographic 100 millisecond X-ray images at 3 mm intervals 
in the space of a short breath-hold, and quantifies the calcified 
plaque in the epicardial coronary arteries. Current state of the 
art MDCT employs a rotating gantry with a special X-ray tube 
and 64 (or more) rows of detectors, with 165 millisecond or 
faster imaging at 3.0 mm intervals. Cardiac scans using ,64 
slice MDCT remain suspect as to their accuracy to quantify 
CAC due to motion and scan timing issues.
CAC is virtually always associated with mural ather-
omatous plaque.20,21 A strong direct relationship has been 
Table 1 Published prognostic studies using CT and CAC in asymptomatic individuals
Author No of 
subjects
Mean 
age 
(years)
Follow 
up 
duration 
(years)
CAC score 
cutpoint
Comparison 
group
Risk 
ratio
Raggi7 632 52 2.7 Highest quartile Lowest quartile 13
wong8 926 54 3.3 Highest quartile Lowest quartile 8.8
Arad9 1,173 53 3.6 CAC Score $ 160 CAC Score , 160 20.2
Kondos10 5,635 51 3.1 CAC Score . 0 CAC Score = 0 10.5
Shaw11 10,377 53 5 CAC . 400 CAC # 10 8.4
Greenland12 66 66 7 CAC . 300 CAC = 0* 3.9*
Arad13 5,585 49 4.3 CAC $ 100 CAC , 100 10.7
Budoff14 25,253 56 6.8 CAC . 400 CAC = 0 9.2
Note: *see caveat on interpretation on this study in text.
Abbreviations: CT, computed tomography; CAC, coronary artery calcification.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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established between CAC as measured by CT and both 
  histological22 and in-vivo intravascular ultrasound23,24 mea-
sures of combined calcified and noncalcified plaque. Thus, 
CAC provides a viable estimate of total coronary plaque 
burden for a given individual and has been found to be a 
powerful predictor of future cardiac events, providing inde-
pendent and incremental information over risk factor based 
assessment in the asymptomatic patient.
The original coronary calcium score as published by 
Agatston and Janowitz6 is determined by site-by-site calcified 
plaque area and calcium lesion peak intensity (density). 
Proper application of the ‘Agatston’ calcium score requires 
‘rules’ for scanner settings (see Table 2) and any deviation 
from these rules invalidates the measurement. It is important 
to note that the original application was defined using EBT 
and it is essential that MDCT scanners be standardized to 
these parameters for any confident comparison to established 
scoring guidelines and for application of scoring based upon 
prior published works. Scanning requires a 3 mm CT slice 
thickness and a threshold for CAC of $130 Hounsfield units 
(CT density) involving $ 1 mm2 area/lesion. MDCT scan-
ners set to ,3 mm slice thickness result in ‘oversampling’ 
and calculated scores higher than that from EBT and scan-
ners set to .3 mm slice thickness result in ‘undersampling’ 
and calculated scores less than that of the EBT published 
standards.
Conventional categories for CAC scoring was originally 
put forward by Rumberger et al25 and the plaque burden 
quantitatively characterized as follows: the zero score (no 
measurable calcified plaque), a score of 1–10 as minimal, 
a score of 11–100 as mild, a score of 101–400 as moderate 
and a score .400 as extensive. Example images represent-
ing these categories are shown in Figure 1. The calcium 
volume score26 is a more reproducible parameter independent 
of maximum calcium density per lesion and considered to 
be better suited for serial studies to track progression or 
regression of atherosclerosis; most available computer 
workstations that allow convenient measurements of the 
calcium score report data for both the Agatston score and 
the volume score but most published investigations report 
data from the Agatston calcium score alone. By comparing 
a subject’s Agatston calcium score to others of the same age 
and gender through the use of large databases of asymptom-
atic subjects, a calcium score percentile rank for any given 
individual patient can be determined.27,28 This is an index of 
the severity but also prematurity or, alternatively, latency 
of atherosclerosis development at a given chronological age 
and gender. Although these widely utilized nomograms are 
useful, it should be understood that variations according to 
ethnicity have been described29–32 but this subject is discussed 
in a later section of this manuscript.
Risk stratification
Key studies
The report of the NCEP ATP III guidelines33 made the 
following recommendation on the basis of existing data at 
the time publication (2002): “Therefore, measurement of 
c  oronary calcium is an option for advanced risk assessment 
in appropriately selected persons. In persons with multiple 
risk factors, high coronary calcium scores (eg, .75th 
percentile for age and sex) denotes advanced coronary 
atherosclerosis and provides a rationale for intensified LDL-
lowering therapy”.
Subsequent to the NCEP guidelines, several major 
reports have highlighted the incremental value of CAC 
to conventional risk factor assessment. In a retrospective 
analysis Kondos et al10 (5,635 asymptomatic, predominantly 
low to medium conventional (Framingham) risk, middle-aged 
patients followed for 37 ± 12 months) found that the presence 
of any CAC by CT was associated with a relative risk (RR) 
for future cardiac events of 10.5, compared to 1.98 and 1.4 
for the presence of the conventional risk factors diabetes and 
smoking, respectively. In women, only CAC was linked to 
future events, with a RR of 2.6; conventional risk factors were 
not related. The presence of CAC also provided prognostic 
information incremental to the subject’s chronological age.
Table 2 Cardiac CT scanning and scoring parameters for application of Agatston coronary calcium scoring (see text for details)
CT Scanner FOV 26 cm
Minimal CT density for calcium $130 HU
CT scanner slice collimation 3.0 mm
Minimal calcium area 1 mm2 (3 pixels)
Scoring by calcified lesion 
Total Agatston Score = sum of all 
scores for all calcified lesions in all 
coronary arteries
calcium area (mm2) × 1 for maximum HU 130–199 
calcium area (mm2) × 2 for maximum HU 200–299 
calcium area (mm2) × 3 for maximum HU 300–399 
calcium area (mm2) × 4 for maximum HU $ 400
Abbreviations: CT, computed tomography; FOV, field of view; HU, hounsfield units.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Shaw et al11 retrospectively analyzed 10,377   asymptomatic 
patients with a 5-year follow up after an initial noncontrast CT 
evaluation. All-cause mortality (United States National Death 
Index listing at follow up) increased proportional to baseline 
CAC score, which was an independent predictor of risk after 
adjusting for all Framingham risk factors (P , 0.001). Superior-
ity of CAC to conventional Framingham risk factor assessment 
was also demonstrated by a significantly greater area under 
the receiver operating characteristic (ROC) curves (0.73 vs 
0.67; P , 0.001). Incremental value of CAC to Framingham 
risk was also established by a significant increase of the area 
under the ROC curves, from 0.72 for Framingham risk to 0.78 
with the addition of CAC (P , 0.001). Stratification of all-
cause mortality risk by CAC score was as effective in women 
as in men. A recent study published by Budoff et al using 
also the National Death Index looked at all-cause mortality in 
.25,000 initially asymptomatic subjects and found similar data 
for   prognostication using the baseline or initial CAC score.14
Greenland et al12 analyzed a population based study of 
1,461 prospectively followed, older asymptomatic subjects, 
who were predominantly medium to high risk, and found that 
CAC scores .300 significantly added prognostic information 
to Framingham risk analysis in the intermediate, 10%–20% 
Framingham risk category.
In the Saint Francis Heart Study,13 a prospective, popu-
lation based study of 5,585 asymptomatic patients, CAC 
scores .100 were associated with RR from 10.4 to 32, 
and transformed conversion of Framingham intermediate 
risk individuals to high or very high risk status. In a subset 
of 1,817 patients with clinical risk factor data, incremental 
information over Framingham scores was documented, 
with areas under the ROC curves of 0.79 for CAC and 0.69 
for Framingham (P = 0.0006). The greatest separation of 
patients who developed nonfatal myocardial infarction (MI) 
or cardiac death in follow-up from those who did not was 
at the Agatston CAC score of 100; which has for nearly the 
CAC score = 0 CAC score = 29
CAC score = 250 CAC score = 1200
Figure 1 Examples of noncontrast coronary calcium CT scans at the base of the heart: top left, CAC score = 0; top right, CAC score = 29; bottom left, CAC score = 250; 
bottom right, CAC score = 1200.
Abbreviations: CT, computed tomography; CAC, coronary artery calcification.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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past decade been considered the cutpoint between mild and 
moderate coronary atherosclerosis.25 Importantly, the 15% 
of patients in the Saint Frances study with initial CAC scores 
in the 100–400 range had a 10-fold increase in RR for any 
cardiovascular event compared to the 33% of individuals 
entered into the study protocol with a zero CAC score.
Applications of total CAC score  
in ethnic sub-groups
In non-Hispanic Caucasians, CT ‘heartscan’ derived   measures 
of the total CAC score predict incident coronary heart disease 
independent of traditional coronary risk factors, as discussed 
above. However, it is has been controversial as to whether 
the CAC score predicts coronary heart disease and prognosis 
across racial or ethnic subgroups. The Multi-Ethnic Study of 
Atherosclerosis (MESA) collected data on risk factors and 
performed noncontrast CT for coronary calcium in a popula-
tion-based, multiethnic sample of 6,722 men and women, of 
whom 38.6% were Caucasian-American, 27.6% were Afri-
can-American, 21.9% were Hispanic-American, and 11.9% 
were Chinese-American. The subjects had no known clinical 
cardiovascular disease at study entry and were followed for 
a median of 3.8 years. In comparison with subjects with no 
coronary calcium (ie, a CAC score of zero), the adjusted risk 
of a coronary event was increased by a factor of 7.73 among 
participants with coronary   calcium scores between 101 and 
300 and by a factor of 9.67 among participants with scores 
above 300 (P , 0.001 for both   comparisons).34 Among the 
four ethnic sub-groups, a doubling of the calcium score 
increased the RR of a major coronary event by 15% to 35% 
and the risk of any coronary event by 18% to 39%. Further-
more, the areas under the ROC curves for the prediction of 
both major coronary events and any coronary event were 
higher when the calcium score was added to standard risk 
factors. The investigators concluded that the total Agatston 
CAC score was a strong predictor of incident coronary heart 
disease and provided similar predictive information beyond 
that provided by standard risk factors in each of the four 
major racial/ethnic sub-groups investigated.
Application of total CAC scores  
in the elderly
The majority of data using the predictive power of the 
total Agatston CAC score have been derived from studies 
done in individuals between 40 and 65 years of age. It is 
well known that the CAC score increases as a function of 
age in both men and women and many have suggested that 
the predictive power of the CAC score may be diminished 
in the elderly in whom the prevalence of any CAC is 
common.
Raggi et al35 reported on the predictive power of the total 
CAC score in a total of 35,383 individuals referred by their 
primary care physician for a ‘heartscan’. Of this group, 3,570 
were above the age of 70 years. The investigators evaluated 
the predictive power of CAC scoring in 6 age deciles from 
individuals ,40 to .80 years of age. The study reaffirmed 
that overall mortality rate increased with each age decile 
(hazard ratio [HR], 1.09) with mortality rates greater for 
men than women (HR, 1.53; P , 0.0001). The authors con-
cluded that CAC risk was different in men and women but 
that even in elderly patients, CAC score was an independent 
prognostic indicator.
Defining heart age vs chronological age
The Framingham risk score (FRS) assesses future ‘risk’ 
from standard risk variables including chronological age 
of the patient, gender, total cholesterol value, high-density 
lipoprotein (HDL) cholesterol value, smoking history, 
and blood pressure (noting if the patient is or is not cur-
rently taking hypertensive medications). Of these values, 
the variables with the greatest influence within the FRS 
model are age and gender. Overall, the FRS defines the 
‘median’ risk for a group of individuals of similar age and 
risk factor status, however conceptually this can be further 
individualized through refinement of patient age as ‘heart age’ 
for the FRS calculation. Grundy36 was the first to suggest this 
approach. Nassir and Rumberger37 expanded on this concept 
by redefining the traditional FRS scoring tables substituting 
‘heart’ age for chronological age using percentile ranking of 
total CAC scores.
Estimation of an individual’s ‘heart age’ can be done in a 
straightforward manner using previously published database 
information. Figure 2 shows a graphical representation of 
CAC score data from asymptomatic men and women origi-
nally presented by Hoff et al.27 Upon this figure is indicated 
information from a male aged 50 years with a total CAC score 
of 100 and a female, aged 55 years, with a total CAC score of 
50. The ‘median’ CAC score for a 50-year-old man is 15 and 
the   corresponding ‘median’ score for a 50-year-old woman is 
1. From the data as shown in Figure 2, these individual total 
CAC scores are more representative of median scores from 
a man age 60 years (ie, 10 years older) and a woman age 70 
years (ie, 15 years older). To illustrate further, assume that both 
are nonsmokers, have a total cholesterol value of 5.83 mmol/L 
(225 mg/dL), an HDL of 1.09 mmol/L (42 mg/dL), and 
both have mild, untreated hypertension with resting systolic Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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blood pressures of 135 mmHg. The subsequent   calculated 
Framingham risk18 for the man (based on chronological age) 
would be 0.7%/year and for the woman 0.2%/year. Using 
the ‘heart age’ (but not   changing the point scores based on 
chronological age points accumulated for the other risk fac-
tors) the cardiovascular ‘risk’ for developing symptomatic 
disease would be 1.2%/year and 0.6%/year for the man 
and women, respectively. These revised risk estimates can 
then be used clinically to guide the level of aggressiveness 
for medical interventions. Heart age and a FRS integrating 
conventional risk factors and a given individual’s CAC score 
can be conveniently calculated at the MESA website at http://
www.mesa-nhlbi.org/CACReference.aspx.
Coronary calcium pattern and distribution
The majority of data regarding the prognostic power of 
CAC has been reported using the total Agatston coronary 
calcium score whereas little has been published regarding 
  calcification patterns and prognosis. A common question is: 
“does a total calcium score of X, attributed to a single site in 
a single coronary artery invoke the same prognostic power 
as the same total calcium score in an individual where the 
distribution is diffuse and found in three separate coronary 
arteries or the left main artery?”
Ehara et al38 studied preintervention intracoronary 
ultrasound in patients with acute coronary syndromes and 
in patients with stable coronary artery disease (CAD) and 
noted that ‘spotty’ coronary calcium (ie, a focus ,3 mm 
in size) was more likely to be associated with an acute 
  presentation. Schmermund et al had noted previously that a 
pattern of ‘spotty’ (mild to moderate diffuse versus moderate 
to severe focal) coronary calcium by CT was more commonly 
  associated with diffuse coronary plaque and focal outward 
(ie, positive) coronary artery remodeling at angiography.39 
Most recently, Williams et al40 reported on 14,759 individuals 
for all-cause mortality at an average of 6.8 years of follow 
up. They noted that the mortality rate exceeded 2% per year 
(considered ‘coronary artery disease’ risk equivalent by 
the NCEP) in the setting of more than 20 calcified lesions. 
Additionally, the finding of CAC in the left main coronary 
artery as opposed to any other anatomic site was associated 
with increased all-cause mortality.
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Figure 2 Graphical representation of data presented by Hoff27 showing distribution of total CAC scores in 35,246 men and women. The red line represents the median 
score as a function of age. Superimposed are information regarding determination of ‘heart age’ (see text for details) in a 50 year old man with a CAC score of 100 and a   
55 year old woman with a CAC score of 50.
Abbreviation: CAC, coronary artery calcification.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
585
Using cardiac CT and CAC for CV risk assessment/management in asymptomatic adults
Quantification of the distribution of coronary artery 
calcium was recently proposed with a ‘calcium coverage 
score’ (CCS) calculated as the proportion of 5 mm coronary 
arterial segments affected by calcific plaque.41 In the MESA, 
after 41 months of follow-up, a two-fold increase in CCS 
was associated with a 34% increased risk of a hard coronary 
disease event, defined as definite adjudicated myocardial 
infarction (MI), coronary death, and/or angina, compared 
with just a 14% increased risk indicated by the total CAC 
Agatston score. Additional validation work is needed on the 
CCS, but in the future, application of the CCS may result in 
further refinement in the assessment of individual risk over 
and above the total CAC score.
The zero score
Asymptomatic individuals with zero CAC score have not 
yet developed detectable, calcified coronary plaque but may 
have fatty streaking and early stages of a plaque and have a 
1%–2% chance of focal obstructive coronary artery disease. 
Atherosclerotic plaques are present in many young adults,42 
but the event rate in patients with CAC score of zero is very 
low.7,10,12,13 Raggi et al7 have demonstrated an annual event 
rate of 0.11% in asymptomatic subjects with 0 scores, and 
in the St Francis Heart Study,13 scores of 0 were associated 
with a 0.12% annual event rate over the ensuing 4.3 years. 
Greenland et al12 in a higher risk asymptomatic cohort, noted 
a higher annual event rate (0.62%) with 0 CAC scores; how-
ever a less sensitive CAC detection technique (significant 
‘under sampling’ and thus ‘under-scoring’ by using higher 
thresholds for positive scans, ie, nonstandard Agatston scor-
ing) and marked ethnic heterogeneity may have contributed 
to their different findings.43
A more definitive study (again using the National Death 
Index) which addressed the issue of a zero CAC score and 
all-cause mortality was reported by Blaha and colleagues.44 
Annualized all-cause mortality was assessed in 44,052 
consecutive asymptomatic adults (age 54 ± 10 years) 
referred for risk assessment using noncontrast CT and CAC 
scoring. Follow up was done at 5.6 ± 2.6 years. A total of 
19,898 subjects had no detectable CAC on initial cardiac 
CT examination. Annualized all-cause mortality rates for 
CAC = 0 were 0.87 deaths/1,000 person years (0.087%/
year). Mortality rates for a CAC score of 1–10 and .10 were 
higher at 1.92 and 7.48/1,000 person years, respectively. 
This confirms that a zero CAC score in an asymptomatic 
individual puts them at a ,0.1%/year mortality risk, but 
scores above zero represent incrementally and substantially 
increased cardiac risk.
Distribution of CAC
There is often confusion as to what would be the typical 
distribution of calcium scores as applied to an asymptom-
atic group of intermediate risk individuals. Misconceptions 
abound as many symptomatic individuals undergoing CT 
coronary angiography are often found to have very high 
calcium scores and many physicians that I have consulted 
with seem to think that ‘everybody who is middle aged has 
some CAC’. This is simply not true.
As an example, I offer information on 5,192   randomly 
assessed, asymptomatic individuals referred to me personally 
for cardiovascular risk assessment by their primary care 
doctors. The average age was 53 ± 10 years (60% men); 
31% had total cholesterol above 5.18 mmol/L (200 mg/dl), 
22% had a systolic blood pressure .140 mmHg, 7% were 
current smokers, and 23% had a family history of premature 
heart disease in a first degree relative. Calcium scores ranged 
from 0 to 5808 (mean 128 ± 378). A zero CAC score was 
found in 47% while a score above 1000 was found in only 
3.5%. A pie chart of the distributions of calcium scores in 
this asymptomatic group is found in Figure 3.
Clinical applications
Patient selection
Recommendations for CAC scanning are not based on age 
and gender alone. Rather, the FRS, which incorporates both 
age and gender, is recommended as the initial step in selecting 
the appropriate test populations. Asymptomatic patients in 
the 10%–20% Framingham 10 year risk category (medium/
intermediate risk) comprise of the group that presents the great-
est challenge to the treating physician, and are those in whom 
the application of CAC scoring is considered most appropriate. 
This group represents up to 40% of the population that might be 
seen sitting in the waiting room of the average internist.45 While 
this application was proposed as being reasonable in the early 
American College of Cardiology/American Heart Association 
(ACC/AHA) consensus statement,46 the recent additional evi-
dence of risk-stratification by CAC in this group has resulted 
in a greater acceptance of its benefits, and was included in 
the 2005 AHA Scientific Statement on noninvasive testing in 
women for use in the intermediate risk population.17
Selected patients with less than intermediate Framingham 
risk may also benefit. For instance, most young patients with 
a family history for premature CAD (1st degree relatives with 
documented heart disease below the age of 55) will not have 
sufficient risk factors to even warrant Framingham scoring 
(lower NCEP risk), or will be in the low (1%–10%) 10 year 
Framingham risk group.18,47 Data from Schmermund et al24 and Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Pohle et al48 indicate that 95% of acute MI patients would have 
been identified by CAC plaque imaging, even in those with a 
mean age of 41 years. On the basis of these observations, the 
use of CAC scoring should be considered in patients with a 
family history of premature CAD, especially if their Framing-
ham risk is intermediate (although many would advocate this 
use even if the initial Framingham risk was calculated as low; 
since family history remains one of the most positive risk fac-
tors and is NOT considered part of conventional Framingham 
Risk scoring).
Selective application of CAC scanning to patients with 
Framingham high risk (.20%/decade or .2%/year) may also 
be warranted. For instance, some Framingham high risk patients 
may be intolerant of statins or may strongly prefer alternative-
medicine approaches. In these patients, CAC confirmation of 
high risk may be used to reinforce the necessity for finding a 
statin that can be tolerated and for persuading the refractory 
patient of the need for aggressive treatment. Conversely, the 
absence of any CAC for age or gender may permit relaxation 
of the treatment goals, an approach that appears justified by the 
low event rate in the 0 score CAC group.7,10,12–14
Initiation and goals of drug therapy
The presence or absence and amount of CAC can be useful 
for clinical decision making, as previously recommended 
in the AHA Prevention V Update.49 As an extension of 
this report, based on recent data, Table 3 provides simple, 
easily implemented treatment paradigms for combining 
risks of varying CAC scores with the most recent NCEP 
  recommendations. Patients in the 10%–20% 10 year risk 
  category that are identified to be at higher risk by CAC 
become candidates for secondary prevention lipid goals 
regardless of their baseline lipid level. This would apply even 
for patients with low-density lipoprotein (LDL) cholesterol 
,2.59 mmol/L (,100 mg/dL), as implied by the Heart 
  Protection Study50 and stated in the prior NCEP report.
Based on prognostic data, CAC scores .100 and/
or .75th percentile for age/gender serves to define a CAD 
risk equivalent (ie, .20% over the next decade). In the St 
Francis Heart Study,13 the CAC cutpoint for secondary pre-
vention risk equivalency in the Framingham intermediate 
10%–20% 10 year risk group was a score .100; or, addition-
ally at a score .75th percentile for age as suggested by the 
NCEP guidelines. In this regard, CAC scores .400 or .90th 
  percentile for age/gender are associated with a very high 
annual risk (4.8% and 6.5% respectively),7,51 and these indi-
viduals are candidates for an even more aggressive approach 
(ie, LDL , 1.81 mmol/L (,70 mg/dL) as suggested by the 
latest update to the NCEP19) and possibly further stratification 
with stress testing (see Discussion below).
Zero
>0, <20 
>20, <100 
>100, <400
>400, <1,000 
>1,000
VL
L
I
H
VH
Agatston CAC Scores
9% VH
13% H
14% I
17% L
47% VL
Figure 3 Pie chart representing the distribution of coronary calcium scores in .5,000 asymptomatic, middle aged adults referred to one scanning center for assistance 
in cardiovascular risk stratification. Subsequent stratification of risk is altered based upon the total calcium scores (see text for detail) as very low (VL = ,0.1%/year), low   
(L = ,1%/year), true intermediate (I = 1%–2%/year), high (H = .2%/year), and very high (VH = .3%/year).Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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In the Framingham 10%–20% 10 year risk population, 
patients with CAC scores #100 and/or #75th percentile 
remain in the same risk group or are transformed to lower risk 
categories depending on the actual score or percentile rank. A 
reasonable approach is to leave the patients with CAC scores 
from 10–100 and ,75th percentile in the intermediate risk 
(10%–20% 10 year risk), and reclassify patients with CAC 
scores from 1–10 and ,75th percentile as low risk (,10% 
10 year risk) and treat accordingly. CAC scores of 0 would 
reclassify the patient to the very low risk category.
As noted above, some patients in the lower risk groups 
based on Framingham scores, such as younger patients 
(35–45 years of age) with a strong family history of premature 
  coronary heart disease, may be appropriately tested with CAC 
scanning. In such patients, the recommendations in Table 3 
would also apply. While it is widely accepted that high CAC 
scores reinforce the intensity of medical therapy, how low CAC 
scores should affect therapy is not yet clear. It would appear 
reasonable that in high risk asymptomatic patients who have 
undergone imaging, CAC scores #100, and in particular, #10, 
imply a lower than expected risk and may reduce the intensity 
of therapy. The rationale for this lowest category is as follows. 
If the use of cholesterol lowering medications (such as statins) 
can across the board, lower the risk of an MI by 1/3, this is 
significantly of value when the risk is found to be high, but 
is less practical when the risk is very low; for instance, if the 
‘risk’ of a cardiovascular event is 0.1%/year for a zero CAC 
score (as supported by the published literature), then using a 
cholesterol medication may be of limited incremental value 
if the risk reduces to 0.07%.
It is important to note, however, that a CAC score of 0 
does not imply that no treatment is necessary. Rather, it is 
used to shift the patient to a lowest risk group. For example, 
early information has shown that the event rate in   diabetics 
with 0 CAC scores is as low as in nondiabetics with 0 scores,52 
potentially creating a group of diabetics who would not have 
to be considered to have ‘coronary heart disease’ equivalence. 
More data is needed in these groups for determining the 
therapeutic implications of the absence of CAC.
Evaluation of treatment
The use of changes in CAC score rather than changes in lipid 
values to track treatment effects has been under investigation. 
Serial CT scanning has shown that aggressive lipid lower-
ing therapy may slow progression of calcified plaque53–58 
although it is far from infallible.59 Clearly, a noninvasive tool 
with which sequential testing could be performed safely and 
reliably would be highly desirable provided the results are 
associated with significant prognostic value. Raggi et al have 
demonstrated that CAC progression was greater in patients 
with future MI58 whereas LDL levels on treatment were 
similar in patients with and without events. Progression was 
associated with a worse prognosis compared to stabilization, 
irrespective of baseline CAC score. However, more studies 
are required to justify the broad based use of serial CAC 
scanning to monitor treatment efficacy.
Triage for stress testing
The asymptomatic middle aged population has a low   pretest 
likelihood for significant obstructive disease (.50%   stenosis); 
nonetheless, stress testing in this group is common even 
though there are no guideline sanctioned recommendations. 
Bayes Theorem60 dictates that stress testing of any kind will 
yield a large proportion of false positives in this low pretest 
likelihood group. CAC scoring is better suited than stress 
testing as the initial assessment; stress testing may be of value 
in selected patients after the CAC test to determine whether 
ischemia is present in order to further guide management 
Table 3 Guidelines for treatment of LDL cholesterol in asymptomatic individuals classified as intermediate risk patients by NCEP 
(Framingham 10%–20% 10 year risk)
CAC score and  
percentile ranking
Framingham risk group 
equivalent
Target LDL goal 
mmol/L (mg/dl)
Pharmacologic therapy 
indicated @ mmol/L (mg/dl)
Zero Very low risk (10 year risk ,1%) ,4.14 (160) $4.92 (190)
.0, ,10 AND 
,75th percentile
Low risk (10 year risk .1%  
but ,10%)
,3.37 (130) $4.14 (160)
11–100 AND 
,75th percentile
Intermediate risk (10 year 
risk .10% but ,20%)
,3.37 (130) $3.37 (130)
101–400 OR $ 
75th but ,90th 
percentile
High risk (coronary disease 
risk equivalent; 10 year  
risk $20%)
,2.59 (100) $2.59 (100)
.400 OR $90th 
percentile
Very high risk (10 year  
risk .30%)
,1.29–1.81 (50–70) any LDL level
Abbreviations: LDL, low-density lipoprotein; NCEP, National Cholesterol Education Program; CAC, coronary artery calcification.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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and in particular to determine whether coronary angiography 
should be considered. Stress testing performed to evaluate 
cardio-respiratory fitness and blood pressure response to 
exercise should not be influenced by CAC.
Based on studies in relatively large groups of patients, it 
is clear that stress testing is not needed in the vast majority 
of asymptomatic patients with CAC scores .0 (see score 
distributions in a sample of such patients in Figure 3). In 411 
patients without established coronary disease undergoing 
CAC scanning and myocardial perfusion imaging (MPI), He 
et al61 found 0% positive nuclear tests with CAC scores of 0 
and 1–10, 2.6% with CAC scores 11–100, 11.6% with CAC 
scores 101–399, and 46% with CAC scores $400. However, 
these high percentages of abnormal MPI in various CAC score 
categories are at odds with the observations of Berman et al.62 
In 1195 patients without known disease, Berman noted 1.6% 
abnormal MPI with CAC scores of 0, 0% with scores of 1–9, 
2.4% with scores of 10–99, 5.2% with scores of 100–399, 
8.9% from 400–999, and 19.9% with scores $1000. However, 
both studies concluded that sufficient pretest likelihood of an 
abnormal MPI is present in the CAC score .400 group and in 
only selected patients in the 100–400 CAC score group. Many 
clinicians now suggest stress testing when the baseline CAC 
score exceeds 400, even if they are asymptomatic. This was 
the same conclusion reached by Rumberger and colleagues 
in the first guidelines paper on CAC scoring, published more 
than a decade ago.25
The study of Berman et al also illustrated that the normal 
MPI study alone, performed without the CAC score, was 
  insufficient to place patients into a group not requiring aggres-
sive medical therapy, even if the short term prognosis is benign. 
They found that 56% of 1195 patients with   normal MPI had 
CAC scores .100, and 31% had CAC scores .400. Thus, if 
the likelihood of CAD was sufficiently high to   warrant stress 
testing with any modality, CAC scanning should be considered 
after a normal stress evaluation to guide the aggressiveness 
of medical therapy.62
Regardless of the CAC score, stress testing should 
  precede coronary arteriography in the asymptomatic patient, 
and coronary angiography should be reserved for those 
patients deemed to be at high risk on the basis of the stress 
test results. However, this group may alternatively be con-
sidered for direct CT angiography (CTA) using 64+-slice 
MDCT.
Limitations
As with any diagnostic method, CAC testing has   limitations. 
It does not evaluate the degree of coronary stenosis; the 
  specificity of a positive CAC score for the presence of 
obstructive disease is in the 40% range.63 In addition, the 
specificity of CAC for cardiac events is quite low, since only a 
minority of patients with CAC experience events. However, the 
specificity of CAC for the diagnostic goal, the identification 
of sub-clinical atherosclerosis, is nearly 100%. CAC does 
not visualize noncalcified (incorrectly deemed ‘soft’) plaque, 
and patients with exclusively   noncalcified plaque will escape 
detection; however, although discussed by clinicians, such a 
situation of significant noncalcified plaque in the absence of 
concomitant calcified plaque somewhere within the coronary 
system is rare in the pathology literature.
CAC scanning is associated with a radiation dose which 
ranges from 0.9 mSv (milli-Severt) for EBT and up to 
2.5 mSv for prospectively gated MDCT. However, awareness 
of the need to reduce radiation doses for routine CT scanning 
has resulted in major improvements in scanning algorithms 
from the MDCT manufacturers. Currently, a retrospective 
CAC scan can be done in almost all situations with radia-
tion doses ,1.5 mSv and commonly at ,1 mSv with the 
latest scanners (the radiation dose for a standard two-view 
mammogram is about 0.75 mSv, to put this in perspective). 
However, the fact that a cardiac CT examination of any type 
does necessitate radiation exposure to the patient emphasizes 
the importance of appropriate patient selection to ensure that 
the benefits outweigh the risks.
The major limitation of this report is the absence of 
evidence based confirmation of the CAC based proposed 
modifications of the NCEP-III guidelines, and the reliance 
on the clinical experience of the authors and extrapola-
tion of risk from key clinical studies, some of which are 
retrospective.
Beyond the coronary arteries
A noncontrast CT of the heart can provide additional   anatomic 
information beyond just defining the amount or pattern of 
CAC. There has been renewed interest in using all potential 
scan information as it might relate to an   individual’s develop-
ment of or risk for developing cardiac disease. In   particular 
three new areas have been most recently examined.
Heart size
Nasir et al64 used data from the MESA study to compare left 
ventricular size from noncontrast CT scans of the heart with 
magnetic resonance imaging (MRI) determinations of left 
ventricular muscle mass and volumes in the same subjects. 
A total of 5,004 participants were included in the investi-
gation. From the ‘heartscan’, a single midventricular CT Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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slice was defined at the level containing the coronary sinus 
or the first level below the left atrium. Then a straight line 
connecting the anterior-posterior junction of both ventricles 
was drawn to divide the left and right ventricles and the 
subsequent area of the left ventricle was then measured with 
planimetry and left ventricular (LV , middiastolic) volume was 
estimated using a previously validated algorithm developed 
by Mao.65 Left ventricular measurements with CT correlated 
well with MRI regarding both LV volume (r = 0.73; P , 0.01) 
and LV muscle mass (r = 0.74; P = 0.01). Further studies 
will be required, but these data clearly indicate that an addi-
tional important parameter for cardiovascular diagnosis and 
prognosis, namely estimates of LV volume/mass, are possible 
from a standardized ‘heartscan’.
Thoracic aorta size
Dilation of the aortic root and the thoracic aorta is common 
in aortic valve disease, primary diseases of the aorta, and 
systemic hypertension. Two-dimensional echocardiography 
is most commonly used clinically for these measurements; 
however, similar anatomic areas are also imaged as part of 
a standard ‘heartscan’. Lin et al66 evaluated noncontrast, 
ungated, scans of the chest/heart in 103 normotensive, 
nonobese individuals who were free of known cardiovas-
cular disease. They reported that normal aortic root size 
(2.5–3.7 cm), ascending aorta diameter (2.1–3.5 cm), and 
thoracic aorta (1.7–2.6 cm) diameters were very similar to 
what had been previously reported using standard transtho-
racic echocardiography. These data imply that prospective 
application of these normative values to individuals under-
going ‘heartscans’ for assessment of coronary calcium may 
provide additional diagnostic information.
Pericardial/epicardial fat
Visceral abdominal/adipose fat has a known association 
with the metabolic syndrome67 and its measurement from 
  abdominal CT scans has been standardized for some time.68 
Recently, an association of visceral adipose fat with   epicardial 
adipose fat on MDCT scans has been noted69 where both were 
found to correlate with body mass index, waist circumfer-
ence, and other known cardiovascular risk factors such as 
coronary and vascular calcification. Recently Nichols and 
colleagues70 have evaluated a three-dimensional volumetric 
measure of epicardial fat using contrast-enhanced MDCT 
and have found it be highly reproducible. However, further 
data are needed to determine the algorithms application to the 
more commonly obtained noncontrast scans done as part of 
standard CAC assessment. An example of a single slice, mid 
LV ‘heartscan’ from a patient without and a patient with meta-
bolic syndrome, demonstrating the epicardial fat distribution, 
is shown on Figure 4. A reliable and reproducible measure 
of epicardial fat would provide yet another potential for the 
‘heartscan’ to be used in cardiovascular risk stratification, 
especially in individuals with the metabolic syndrome.
Conclusions
The increasing use of CAC scanning for risk assessment 
is now supported by extensive evidence in appropriately 
selected patients. Critical to its implementation is the 
  ability of practitioners to understand the CAC scoring 
data and limitations of the test, as outlined in this review. 
Only then can they appropriately utilize this knowledge, 
including data ‘beyond the coronary arteries’, to improve 
cardiovascular risk assessment and management in their 
individual patients.
Figure 4 A single, mid LV slice from a noncontrast CT of the heart (ie, a ‘heartscan’) demonstrating the epicardial fat distribution in a patient without metabolic syndrome 
(Left arrow) and a patient with known metabolic syndrome (right arrow). See text for details.
Abbreviations: LV, left ventricle; CT, computed tomography.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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